Increased Rate of Spontaneous Bacterial Peritonitis Among Cirrhotic Patients Receiving Pharmacologic Acid Suppression

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 4, 2012, Pages 422-427

  Goel, Gati A ^a   Deshpande, Abhishek ^a   Lopez, Rocio ^a   Hall, Geraldine S ^a   van Duin, David ^a   Carey, William D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Bacterial infection; H2 blocker; Hepatitis; Stomach

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BACTERIAL PERITONITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPONATREMIA; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PARACENTESIS; SPONTANEOUS BACTERIAL PERITONITIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PERITONITIS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES;

EID: 84858703547     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.11.019     Document Type: Article

References (29)

1. Pinzello G., Simonetti R.G., Craxì A., et al. Spontaneous bacterial peritonitis: a prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983, 3:545-549.
2. Andreu M., Sola R., Sitges-Serra A., et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993, 104:1133-1138.
3. Titó L., Rimola A., Ginès P., et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988, 8:27-31.
4. Garcia-Tsao G., Albillos A., Barden G.E., et al. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993, 17:1081-1085.
5. Fiuza C., Salcedo M., Clemente G., et al. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000, 182:526-533.
6. Runyon B.A. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 1988, 8:632-635.
7. McColl K.E., Kennerley P. Proton pump inhibitors-differences emerge in hepatic metabolism. Dig Liver Dis 2002, 34:461-467.
8. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002, 19:911-927.
9. Prod'hom G., Leuenberger P., Koerfer J., et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994, 120:653-662.
10. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
11. Ferron G.M., Preston R.A., Noveck R.J., et al. Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. Clin Ther 2001, 23:1180-1192.
12. Hoyumpa A.M., Trevino-Alanis H., Grimes I., et al. Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther 1999, 21:691-701.
13. Swan S.K., Hoyumpa A.M., Merritt G.J. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999, 13(Suppl 3):11-17.
14. Chavez-Tapia N.C., Tellez-Avila F.I., Garcia-Leiva J., et al. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit 2008, 14:CR468-CR472.
15. Gimson A., Polson R., Westaby D., et al. Omeprazole in the management of intractable esophageal ulceration following injection sclerotherapy. Gastroenterology 1990, 99:1829-1831.
16. Rolando N., Harvey F., Brahm J., et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology 1990, 11:49-53.
17. Waldum H.L., Brenna E., Sandvik A.K. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf 2002, 1:29-38.
18. Yang Y.X., Lewis J.D., Epstein S., et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953.
19. Cirera I., Bauer T.M., Navasa M., et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001, 34:32-37.
20. Campbell M.S., Obstein K., Reddy K.R., et al. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008, 53:394-398.
21. Bauer T.M., Steinbrückner B., Brinkmann F.E., et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001, 96:2962-2967.
22. Northup P.G., Argo C.L., Berg C.L. Chronic proton pump inhibitor use is strongly associated with hepatorenal syndrome and spontaneous bacterial peritonitis in cirrhosis patients. Hepatology 2008, 48:325A.
23. Bajaj J.S., Zadvornova Y., Heuman D.M., et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009, 104:1130-1134.
24. Grube R.R., May D.B. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007, 64:1396-1400.
25. Lassen A., Hallas J., Schaffalitzky De Muckadell O.B. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther 2004, 20:577-583.
26. Jacobson B.C., Ferris T.G., Shea T.L., et al. Who is using chronic acid suppression therapy and why?. Am J Gastroenterol 2003, 98:51-58.
27. Guda N.M., Noonan M., Kreiner M.J., et al. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage?. Am J Gastroenterol 2004, 99:1233-1237.
28. Caruntu F.A., Benea L. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointest Liver Dis 2006, 15:51-56.
29. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2056. quiz, 2057.